Anticancer Activity of Nicotinamide on Lung Cancer
Status:
Active, not recruiting
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate
epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer
cells. Nicotinamide was found to be effective in several animal cancer models including lung,
bladder, liver, etc. The purpose of this study is to determine whether nicotinamide is also
effective in the treatment of human lung cancer.